Literature DB >> 17252022

Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals.

N C Gutiérrez1, E M Ocio, J de Las Rivas, P Maiso, M Delgado, E Fermiñán, M J Arcos, M L Sánchez, J M Hernández, J F San Miguel.   

Abstract

The tumoral clone of Waldenström's macroglobulinemia (WM) shows a wide morphological heterogeneity, which ranges from B lymphocytes (BL) to plasma cells (PC). By means of genome-wide expression profiling we have been able to identify genes exclusively deregulated in BL and PC from WM, but with a similar expression pattern in their corresponding cell counterparts from chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), as well as normal individuals. The differentially expressed genes have important functions in B-cell differentiation and oncogenesis. Thus, two of the genes downregulated in WM-BL were IL4R, which plays a relevant role in CLL B-cell survival, and BACH2, which participates in the development of class-switched PC. Interestingly, one of the upregulated genes in WM-BL was IL6. A set of four genes was able to discriminate clonal BL from WM and CLL: LEF1 (WNT/beta-catenin pathway), MARCKS, ATXN1 and FMOD. We also found deregulation of genes involved in plasma cell differentiation such as PAX5, which was overexpressed in WM-PC, and IRF4 and BLIMP1, which were underexpressed. In addition, three of the target genes activated by PAX5 - CD79, BLNK and SYK - were upregulated in WM-PC. In summary, these results indicate that both PC and BL from WM are genetically different from the MM and CLL cell counterpart.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17252022     DOI: 10.1038/sj.leu.2404520

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  76 in total

1.  The eleven-nineteen lysine-rich leukemia gene (ELL2) influences the histone H3 protein modifications accompanying the shift to secretory immunoglobulin heavy chain mRNA production.

Authors:  Christine Milcarek; Michael Albring; Creityeka Langer; Kyung Soo Park
Journal:  J Biol Chem       Date:  2011-08-09       Impact factor: 5.157

Review 2.  Molecular pathogenesis of Waldenstrom's macroglobulinemia.

Authors:  Esteban Braggio; Casey Philipsborn; Anne Novak; Lucy Hodge; Stephen Ansell; Rafael Fonseca
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

Review 3.  Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia.

Authors:  Ying Huang; Jia-Zhu Wu; Jian-Yong Li; Wei Xu
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

4.  Identification of certain cancer-mediating genes using Gaussian fuzzy cluster validity index.

Authors:  Anupam Ghosh; Rajat K De
Journal:  J Biosci       Date:  2015-10       Impact factor: 1.826

5.  Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset.

Authors:  Edgar D Charles; Claudia Brunetti; Svetlana Marukian; Kimberly D Ritola; Andrew H Talal; Kristen Marks; Ira M Jacobson; Charles M Rice; Lynn B Dustin
Journal:  Blood       Date:  2011-03-18       Impact factor: 22.113

6.  Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.

Authors:  Lucía López-Corral; Luis Antonio Corchete; María Eugenia Sarasquete; María Victoria Mateos; Ramón García-Sanz; Encarna Fermiñán; Juan-José Lahuerta; Joan Bladé; Albert Oriol; Ana Isabel Teruel; María Luz Martino; José Hernández; Jesús María Hernández-Rivas; Francisco Javier Burguillo; Jesús F San Miguel; Norma C Gutiérrez
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

7.  Metabolomics identifies pyrimidine starvation as the mechanism of 5-aminoimidazole-4-carboxamide-1-β-riboside-induced apoptosis in multiple myeloma cells.

Authors:  Carolyne Bardeleben; Sanjai Sharma; Joseph R Reeve; Sara Bassilian; Patrick Frost; Bao Hoang; Yijiang Shi; Alan Lichtenstein
Journal:  Mol Cancer Ther       Date:  2013-04-12       Impact factor: 6.261

8.  CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.

Authors:  Y-T Tai; Y Landesman; C Acharya; Y Calle; M Y Zhong; M Cea; D Tannenbaum; A Cagnetta; M Reagan; A A Munshi; W Senapedis; J R Saint-Martin; T Kashyap; S Shacham; M Kauffman; Y Gu; L Wu; I Ghobrial; F Zhan; A L Kung; S A Schey; P Richardson; N C Munshi; K C Anderson
Journal:  Leukemia       Date:  2013-04-16       Impact factor: 11.528

9.  IRF4 addiction in multiple myeloma.

Authors:  Arthur L Shaffer; N C Tolga Emre; Laurence Lamy; Vu N Ngo; George Wright; Wenming Xiao; John Powell; Sandeep Dave; Xin Yu; Hong Zhao; Yuxin Zeng; Bangzheng Chen; Joshua Epstein; Louis M Staudt
Journal:  Nature       Date:  2008-06-22       Impact factor: 49.962

10.  The forkhead transcription factor FOXP1 represses human plasma cell differentiation.

Authors:  Martine van Keimpema; Leonie J Grüneberg; Michal Mokry; Ruben van Boxtel; Menno C van Zelm; Paul Coffer; Steven T Pals; Marcel Spaargaren
Journal:  Blood       Date:  2015-08-19       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.